Potentially earning £129 million from the adenosine receptor antagonist technology with a market cap of £200 million would suggest to me that this company may well be undervalued (of course this subject to development, regulatory and sales milestones being achieved) With £70.6 million of cash resources according to the last set of results on the balance sheet and no debt i would say this company is sound This is why Neil Woodford owns over 15% of the company. This company has a very bright future
But just noticed MCAP! :D
Vernalis plc today announces that it has licensed exclusive, worldwide rights in its adenosine receptor antagonist programme, including the lead drug candidate, V81444, for use in all therapeutic applications to a well-funded, US-based biotechnology company. The transaction includes a $1 million upfront payment and has the potential for Vernalis to earn over $200 million subject to development, regulatory and sales milestones being achieved. In addition there are single digit royalties payable if a product reaches the market, with the potential to reach double digit royalties in certain circumstances
Woodford has gone from 10% to 15% since November 5th. The strange thing is that there has been no mention of it, in his portfolio fund round up......Is he still buying and wants to keep it under the radar?......Is it for his new Patience Fund?......
thanks for the info.
18 Feb '15
I believe the marketing campaign along with the sp, will all spring into action in May, hopefully, after the NDA approval for CCP-01....Tuzistra.. Woodford is mopping up all the sells, going from 12% to 15% in the last 4 month.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.